Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: In Vitro Models

Schentag JJ Meagher AK Forrest A . Fluoroquinolone AUIC Breakpoints and the link to bacterial killing rates. Part 1: in vitro models. Ann Pharmacother 2003; 37: 1287–98. DOI 10.1345/aph1C199

Drusano GL Preston SL Owens RC Jr Ambrose PG . Fluoroquinolone pharmacodynamics. Clin Infect Dis 2001; 33: 2091–6.

Wright DH Brown GH Peterson ML Rotschafer JC . Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669–83.

Coyle EA Kaatz GW Rybak MJ . Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 1654–9.

MacGowan AP Rogers CA Holt HA Bowker KE . Activities of moxifloxacin against and emergence of resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2002; 47: 1088–95.

Cars O . Pharmacokinetics of antibiotics in tissues and tissue fluids: a review. Scand J Infect Dis Suppl 1990; 74: 23–33.

Liu P Muller M Derendorf H . Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 2002; 19: 285–90.

Mouton JW Dudley MN Cars O Derendorf H Drusano GL . Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 2002; 19: 355–8.

Mouton JW . Breakpoints: current practice and future perspectives. Int J Antimicrob Agents 2002; 19: 323–31.

Firsov AA Zinner SH . Use of modeling techniques to aid in antibiotic selection. Curr Infect Dis Rep 2001; 3: 35–43.

Firsov AA Vostrov SN Shevchenko AA Cornaglia G . Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration–time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 1997; 41: 1281–7.

Firsov AA Vostrov SN Shevchenko AA Portnoy YA Zinner SH . A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother 1998; 42: 2841–7.

Firsov AA Shevchenko AA Vostrov SN Zinner SH . Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42: 659–65.

Firsov AA Lubenko IY Portnoy YA Zinner SH Vostrov SN . Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother 2001; 45: 927–31.

Zhanel GG Karlowsky J Palatnick L Vercaigne L Low DE , the Canadian Respiratory Infection Study Group, Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: results of a Canadian national surveillance study. Antimicrob Agents Chemother 1999; 43: 2504–9.

Zhanel GG Palatnick L Nichol K Bellyou T Low DE Hoban DJ . Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867–74.

Ho PL Yung RWH Tsang DNC Que TL Ho M Seto WH , Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659–65.

Nichol K Zhanel GG Hoban DJ . Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada. Antimicrob Agents Chemother 2003; 47: 804–8.

Zhanel GG Walters M Roberts D Laing N Hoban DJ . Pharmacodynamics of fluoroquinolones vs. multi-drug resistant S. pneumoniae simulating free serum concentrations. J Antimicrob Chemother 2001; 47: 435–40.

Zhanel GG Ennis K Vercaigne L Walkty A Gin AS Embil J , The new fluoroquinolones: focus on respiratory infections. Drugs 2002; 62: 13–59.

Zhanel GG Walkty A Nichol K Smith H Noreddin A Hoban DJ . Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003; 45: 63–7.

Chen DK McGeer A de Azavedo JC Low DE . Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233–9.

Davidson R Cavacanti R Brunton JL Bast D De Azavedo JCS Kibsey P . Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 10: 747–50.

Zhanel GG Hoban DJ Chan CK . Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia (letter). N Engl J Med 2002; 347: 65–7.

Smith H Nichol K Hoban DJ Zhanel GG . Impact of parC mutations and efflux on the mutant prevention concentrations (MPC's) of fluoroquinolones (FQ's) in Streptococcus pneumoniae (SPN). Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27–30, 2002.